{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    15,
    35,
    36,
    39,
    40,
    43
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Reference to Clinical Laboratory Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from the Schedule of Activities on page 16 to Appendix 2 for details on laboratory tests."
      },
      {
        "id": "ref_2",
        "name": "Reference to Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9 to Section 2 for the timing of study procedures."
      },
      {
        "id": "ref_3",
        "name": "Reference to Laboratory Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 9 to Appendix 2 for the list of laboratory tests to be performed."
      },
      {
        "id": "ref_4",
        "name": "Reference to Blood Sampling Summary",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Blood Sampling Summary",
        "description": "Reference from Section 9 to Appendix 5 for a summary of the maximum number and volume of invasive samples."
      },
      {
        "id": "ref_5",
        "name": "Reference to Post Glucagon Administration Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.3",
        "sectionTitle": "Post Glucagon Administration",
        "description": "Reference from Section 9.1 to Section 9.2.3 for details on plasma glucose level measurement."
      },
      {
        "id": "ref_6",
        "name": "Reference to Edinburgh Hypoglycemia Scale",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "description": "Reference from Section 9.1.3 to Appendix 7 for the self-reported assessment tool for hypoglycemia symptoms."
      },
      {
        "id": "ref_7",
        "name": "Reference to Schedule of Activities for Assessment Timing",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.1.3 to Section 2 for the timing of hypoglycemia symptom assessments."
      },
      {
        "id": "ref_8",
        "name": "Reference to Clarke Hypoglycemia Awareness Survey",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
        "description": "Reference from Section 9.1.3 to Appendix 8 for the self-report assessment tool."
      },
      {
        "id": "ref_9",
        "name": "Reference to Schedule of Activities for PK/PD Sampling",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.2.1 to the Schedule of Activities for timing of PG and glucagon measurements."
      },
      {
        "id": "ref_10",
        "name": "Reference to Treatment Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Treatment",
        "description": "Reference from Section 9.2.2 to Section 7 for details regarding treatments."
      },
      {
        "id": "ref_11",
        "name": "Reference to Nasal and Non-nasal Score Questionnaire",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "description": "Reference from Section 9.2.2.1 to Appendix 6 for a copy of the questionnaire."
      },
      {
        "id": "ref_12",
        "name": "Reference to Laboratory Tests Appendix from Safety Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 9.5.1 to Appendix 2 for details on laboratory tests."
      },
      {
        "id": "ref_13",
        "name": "Reference to Schedule of Activities from Safety Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.5 to Section 2 for the timing of safety assessments including lab tests, vital signs, and ECGs."
      },
      {
        "id": "ref_14",
        "name": "Reference to Hepatic Monitoring Tests Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
        "description": "Reference from Section 9.5.5.2 to Appendix 4 for the list of liver tests to be repeated upon abnormality."
      },
      {
        "id": "ref_15",
        "name": "Reference to Schedule of Activities for Pharmacokinetics",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9.6 to Section 2 for specified times of venous blood sample collection."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidential Information",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 16
      },
      {
        "id": "annot_3",
        "text": "If a patient sneezes immediately after administration, document using the Nasal and Non-nasal Score Questionnaire (see Appendix 6 for a copy of the questionnaire).",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.2.2.1. Nasal LY900018 Administration",
        "pageNumber": 37
      },
      {
        "id": "annot_4",
        "text": "However, if an SAE occurs after signing informed consent, but prior to receiving investigational product, AND is considered reasonably possibly related to a study procedure then it MUST be reported.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3.1. Serious Adverse Events",
        "pageNumber": 40
      },
      {
        "id": "annot_5",
        "text": "Pregnancy (maternal or paternal exposure to investigational product) does not meet the definition of an AE. However, to fulfill regulatory requirements any pregnancy should be reported following the SAE process to collect data on the outcome for both mother and fetus.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3.1. Serious Adverse Events",
        "pageNumber": 40
      },
      {
        "id": "annot_6",
        "text": "Only severe hypoglycemic episodes will be reported separately as AEs. If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious in the CRF (that is, recorded as an SAE).",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.5.5.1. Hypoglycemic Event Reporting",
        "pageNumber": 44
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "I8R-JE-IGBJ(a)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Protocol Amendment (a) electronically signed and approved.",
        "amendmentNumber": "Amendment (a)"
      }
    ],
    "summary": {
      "referenceCount": 15,
      "annotationCount": 6,
      "versionCount": 1
    }
  }
}